Advertisement

Topics

Athera Biotechnologies AB Company Profile

12:30 EDT 23rd September 2017 | BioPortfolio

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.


News Articles [116 Associated News Articles listed on BioPortfolio]

Athera Biotechnologies Completes Financing To Advance Clinic With Immunovascular Antibody

  Life Sciences Jobs   ...

Athera Biotechnologies Completes Financing To Advance Clinic With Immunovascular Antibody Aug 29, 2017

  Life Sciences Jobs   ...

Athera Biotechnologies Concludes Follow-Up Visits In Multiple Dosing Trial With Its Immunovascular Antibody

  Life Sciences Jobs   ...

Athera Biotechnologies Receives FDA Orphan Drug Designation For PC-mAB In Prevention Of Vascular Access Failure In Kidney Disease Patients

  Life Sciences Jobs   ...

Athera Biotechnologies Release: Proteomics Used To Investigate Effects On Inflammation Response Following Vascular Surgery And Treatment With The Immunovascular Antibody PC-mAb

  Life Sciences Jobs   ...

Athera Biotechnologies AB Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAthera Biotechnologies AB Athera is a biopharmaceutical company that develops targeted anti inflammatory biological candidate drugs and companion diagnostics for cardiovascular disease. The com...

DGAP-HV: Elanix Biotechnologies AG: -2-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

DGAP-HV: Elanix Biotechnologies AG: -3-

DJ DGAP-HV: Elanix Biotechnologies AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.08.2017 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG Dow Jones hat von EQS/D....

Drugs and Medications [0 Results]

None

PubMed Articles [17 Associated PubMed Articles listed on BioPortfolio]

Maintaining US Leadership in Emerging Biotechnologies to Grow the Economy of the Future.

Sourdough-Based Biotechnologies for the Production of Gluten-Free Foods.

Sourdough fermentation, a traditional biotechnology for making leavened baked goods, was almost completely replaced by the use of baker's yeast and chemical leavening agents in the last century. Recen...

Optimization of protocols for Iberian red deer (Cervus elaphus hispanicus) sperm handling before sex sorting by flow cytometry.

Currently, sperm reproductive biotechnologies such as sex sorting and cryopreservation are undoubtedly valuable tools for improving the economic and biological efficiency of red deer production system...

Sharpening the cutting edge: additional considerations for the UK debates on embryonic interventions for mitochondrial diseases.

In October 2015 the UK enacted legislation to permit the clinical use of two cutting edge germline-altering, IVF-based embryonic techniques: pronuclear transfer and maternal spindle transfer (PNT and ...

Is De-extinction Special?

I have been involved with the current interest in de-extinction since early 2012, nearly its beginning. I have given a lot of thought to the potential risks and benefits of de-extinction. But only rec...

Clinical Trials [0 Results]

None

Companies [102 Associated Companies listed on BioPortfolio]

Athera Biotechnologies AB

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two b...

Athera Biotechnologies & ALPCO

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two b...

RAN Biotechnologies

Based in Beverly, MA, USA, RAN Biotechnologies, Inc., www.ranbiotechnologies.com, provides chemicals specially optimized for microfluidic and biotechnological applications. Partic...

Open Therapeutics

Open Therapeutics (http://OpenTherapeutics.org) is a crowdsourcing life science firm that creates and attracts therapeutic biotechnologies and crowdsources them for the global ...

Genemed Biotechnologies Incorporated

Genemed Biotechnologies Inc. provides high quality contract manufacturing services for a wide variety of research and diagnostic products including native or recombinant proteins and nucleotides

More Information about "Athera Biotechnologies AB" on BioPortfolio

We have published hundreds of Athera Biotechnologies AB news stories on BioPortfolio along with dozens of Athera Biotechnologies AB Clinical Trials and PubMed Articles about Athera Biotechnologies AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athera Biotechnologies AB Companies in our database. You can also find out about relevant Athera Biotechnologies AB Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record